AEterna Zentaris' CEO Discusses Q3 2012 Results – Earnings Call Transcript

Published December 13, 2012

AEterna Zentaris' CEO Discusses Q3 2012 Results – Earnings Call Transcript
Filed under: dual diagnosis group therapy

Treatment with AEZS-130 in cancer-cachexia may lead to better quality of life for patients, especially since there are no approved treatments for this condition. Now regarding AEZS-130 as a diagnostic test in adult growth hormone deficiency: subsequent …
{Source}

Study finds several osteoporosis risk factors among post-menopausal women on …
Filed under: dual diagnosis group therapy

A preliminary study of 127 post-menopausal women on hormone replacement therapy in Portugal suggests that there are several risk factors associated with osteoporosis and bone fracture these include age, low bone mineral density, a sedentary lifestyle …
{Source}

U.S. Patents Awarded to Inventors in Michigan (Dec. 9)
Filed under: dual diagnosis group therapy

9 — The University of Michigan, Ann Arbor, Mich., has been assigned a patent (8,323,246) developed by four co-inventors for a "dual drug delivery device." The co-inventors are Srinivas Chiravuri, Ann Arbor, Mich., Allan … In various embodiments, the …
{Source}